Biotechnology companies and academic researchers around the world have been in hot pursuit of oncology’s holy grail – safe, effective T cell-driven therapies for solid tumors. A therapy that can leverage our body’s potent killer T cells to target and destroy tumor tissue while minimizing damage to non-malignant bystanders.
In fact, we are already witnessing the emergent power of cancer immunotherapy, which include immune checkpoint inhibitors (ICIs), adoptive cell...